Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Thomas Budd

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patientsDavid G Hicks, Brian J Yoder, Sarah Short, et al.
Breast Cancer Research and Treatment|January 12, 2013
Supplement use during an intergroup clinical trial for breast cancer (S0221)Gary R Zirpoli, Patrick M Brennan, Chi-Chen Hong, et al.
Journal of the National Cancer Institute|March 17, 2018
Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP StudyGary R Zirpoli, Susan E McCann, Lara E Sucheston-Campbell, et al.
Breast Cancer Research and Treatment|September 30, 2008
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapyYi Zhang, Anieta M Sieuwerts, Michelle McGreevy, et al.
Breast Cancer Research : BCR|November 30, 2018
Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221)Jennifer M Mongiovi, Gary R Zirpoli, Rikki Cannioto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast CancerAvia D Wilkerson, Prerana Bangalore Parthasarathy, Nickolas Stabellini, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
JAMA Network Open|May 4, 2023
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast CancerRikki A Cannioto, Kristopher M Attwood, Evan W Davis, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patientsDavid G Hicks, Brian J Yoder, Sarah Short, et al.
Breast Cancer Research and Treatment|January 12, 2013
Supplement use during an intergroup clinical trial for breast cancer (S0221)Gary R Zirpoli, Patrick M Brennan, Chi-Chen Hong, et al.
Journal of the National Cancer Institute|March 17, 2018
Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP StudyGary R Zirpoli, Susan E McCann, Lara E Sucheston-Campbell, et al.
Breast Cancer Research and Treatment|September 30, 2008
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapyYi Zhang, Anieta M Sieuwerts, Michelle McGreevy, et al.
Breast Cancer Research : BCR|November 30, 2018
Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221)Jennifer M Mongiovi, Gary R Zirpoli, Rikki Cannioto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast CancerAvia D Wilkerson, Prerana Bangalore Parthasarathy, Nickolas Stabellini, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
JAMA Network Open|May 4, 2023
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast CancerRikki A Cannioto, Kristopher M Attwood, Evan W Davis, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
Pageof 11